+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Medical Morphine Market Size and Forecast, By Route of Administration, By Indication and Trend Analysis, 2014-2024

  • ID: 4659634
  • Report
  • September 2017
  • Region: Global
  • 75 pages
  • Hexa Research
1 of 3

FEATURED COMPANIES

  • Alcaliber S.A.
  • NORTHEAST PHARM
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Verve Health Care Ltd.
  • MORE
“Medical Morphine Market Size and Forecast, By Route of Administration (Oral, Injectable), By Indication (Cancer, Arthritis) and Trend Analysis, 2014-2024

The global medical morphine market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine. Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alcaliber S.A.
  • NORTHEAST PHARM
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Verve Health Care Ltd.
  • MORE
Chapter 1. Market Summary
1.1. Market trends & movement

Chapter 2. Global Medical Morphine Market Trends: Drivers & Opportunities
2.1. Introduction
2.2. Key industry trends
2.3. Market drivers
2.4. Market restraints
2.5. Value chain analysis
2.6. Porter's Five Forces analysis
2.7. SWOT

Chapter 3. Global Medical Morphine Market Trends, By Route of Administration
3.1. Global medical morphine market movement, by route of administration, 2016 & 2024
3.1.1. Oral
3.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)
3.1.2. Injectables
3.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)
3.1.3. Others
3.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million)

Chapter 4. Global Medical Morphine Market Trends, By Indication
4.1. Global medical morphine market movement, by indication, 2016 & 2024
4.1.1. Cancer
4.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)
4.1.2. Arthritis
4.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)
4.1.3. Others
4.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million

Chapter 5. Global Medical Morphine Market Trends, By Region
5.1. Global medical morphine market movement, by region, 2016 & 2024
5.1.1. North America
5.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)
5.1.1.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
5.1.1.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
5.1.2. Europe
5.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)
5.1.2.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
5.1.2.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
5.1.3. Asia Pacific
5.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million)
5.1.3.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
5.1.3.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
5.1.4. Rest of the World
5.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million)
5.1.4.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
5.1.4.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

Chapter 6. Key Country Markets
6.1. U.S.
6.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)
6.1.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
6.1.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
6.2. Germany
6.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)
6.2.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
6.2.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
6.3. China
6.3.1. Market estimates and forecast, 2014 - 2024 (USD Million)
6.3.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
6.3.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)
6.4. India
6.4.1. Market estimates and forecast, 2014 - 2024 (USD Million)
6.4.2. Market estimates and forecast, by route of administration, 2014 - 2024 (USD Million)
6.4.3. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

Chapter 7. Competitive Landscape
7.1. Competitive landscape analysis, 2016
7.2. Strategic framework
7.3. Potential customer base concentration
7.4. Company market positioning
7.5. Company profiles
7.5.1. Mallinckrodt Pharmaceuticals
7.5.1.1. Company Overview
7.5.1.2. Product Benchmarking
7.5.1.3. Financial Performance
7.5.1.4. Recent Initiatives
7.5.2. Alcaliber S.A.
7.5.2.1. Company Overview
7.5.2.2. Product Benchmarking
7.5.2.3. Financial Performance
7.5.2.4. Recent Initiatives
7.5.3. Purdue Pharma L.P.
7.5.3.1. Company Overview
7.5.3.2. Product Benchmarking
7.5.3.3. Financial Performance
7.5.3.4. Recent Initiatives
7.5.4. Pfizer Inc.
7.5.4.1. Company Overview
7.5.4.2. Product Benchmarking
7.5.4.3. Financial Performance
7.5.4.4. Recent Initiatives
7.5.5. Johnson Matthey Fine Chemicals
7.5.5.1. Company Overview
7.5.5.2. Product Benchmarking
7.5.5.3. Financial Performance
7.5.5.4. Recent Initiatives
7.5.6. Sun Pharmaceutical Industries Ltd.
7.5.6.1. Company Overview
7.5.6.2. Product Benchmarking
7.5.6.3. Financial Performance
7.5.6.4. Recent Initiatives
7.5.7. Verve Health Care Ltd.
7.5.7.1. Company Overview
7.5.7.2. Product Benchmarking
7.5.7.3. Financial Performance
7.5.7.4. Recent Initiatives
7.5.8. Taj Pharmaceuticals Limited
7.5.8.1. Company Overview
7.5.8.2. Product Benchmarking
7.5.8.3. Financial Performance
7.5.8.4. Recent Initiatives
7.5.9. NORTHEAST PHARM
7.5.9.1. Company Overview
7.5.9.2. Product Benchmarking
7.5.9.3. Financial Performance
7.5.9.4. Recent Initiatives
7.5.10. MANUS AKTTEVA BIOPHARMA LLP
7.5.10.1. Company Overview
7.5.10.2. Product Benchmarking
7.5.10.3. Financial Performance
7.5.10.4. Recent Initiatives
7.5.11. List of other vendors

Chapter 8. Methodology and Scope
8.1. Research methodology
8.2. Research Scope & Assumptions
8.3. List of data sources

*List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Mallinckrodt Pharmaceuticals
  • Alcaliber S.A.
  • Purdue Pharma L.P.
  • Pfizer Inc.
  • Johnson Matthey Fine Chemicals
  • Sun Pharmaceutical Industries Ltd.
  • Verve Health Care Ltd.
  • Taj Pharmaceuticals Limited
  • NORTHEAST PHARM
  • MANUS AKTTEVA BIOPHARMA LLP
Note: Product cover images may vary from those shown
Adroll
adroll